vs
Amphastar Pharmaceuticals, Inc.（AMPH）とCSW INDUSTRIALS, INC.（CSW）の財務データ比較。上の社名をクリックして会社を切り替えられます
CSW INDUSTRIALS, INC.の直近四半期売上が大きい（$233.0M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.3倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 4.4%、差は8.9%）。CSW INDUSTRIALS, INC.の前年同期比売上増加率が高い（20.3% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $22.7M）。過去8四半期でCSW INDUSTRIALS, INC.の売上複合成長率が高い（5.1% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
AMPH vs CSW — 直接比較
売上が大きい
CSW
1.3倍大きい
$183.1M
売上成長率が高い
CSW
+22.1%の差
-1.8%
純利益率が高い
AMPH
純利益率が8.9%高い
4.4%
フリーキャッシュフローが多い
AMPH
FCF $1.9M多い
$22.7M
2年売上CAGRが高い
CSW
2年複合成長率
3.2%
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $233.0M |
| 純利益 | $24.4M | $10.3M |
| 粗利率 | 46.8% | 39.7% |
| 営業利益率 | 19.4% | 7.4% |
| 純利益率 | 13.3% | 4.4% |
| 売上前年比 | -1.8% | 20.3% |
| 純利益前年比 | -35.7% | -61.9% |
| EPS（希薄化後） | $0.51 | $0.62 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上AMPHCSW
| Q4 25 | $183.1M | $233.0M | ||
| Q3 25 | $191.8M | $277.0M | ||
| Q2 25 | $174.4M | $263.6M | ||
| Q1 25 | $170.5M | $230.5M | ||
| Q4 24 | $186.5M | $193.6M | ||
| Q3 24 | $191.2M | $227.9M | ||
| Q2 24 | $182.4M | $226.2M | ||
| Q1 24 | $171.8M | $210.9M |
純利益AMPHCSW
| Q4 25 | $24.4M | $10.3M | ||
| Q3 25 | $17.4M | $40.7M | ||
| Q2 25 | $31.0M | $40.9M | ||
| Q1 25 | $25.3M | $35.1M | ||
| Q4 24 | $38.0M | $26.9M | ||
| Q3 24 | $40.4M | $36.1M | ||
| Q2 24 | $37.9M | $38.6M | ||
| Q1 24 | $43.2M | $31.8M |
粗利率AMPHCSW
| Q4 25 | 46.8% | 39.7% | ||
| Q3 25 | 51.4% | 43.0% | ||
| Q2 25 | 49.6% | 43.8% | ||
| Q1 25 | 50.0% | 44.2% | ||
| Q4 24 | 46.5% | 41.4% | ||
| Q3 24 | 53.3% | 45.6% | ||
| Q2 24 | 52.2% | 47.5% | ||
| Q1 24 | 52.4% | 44.4% |
営業利益率AMPHCSW
| Q4 25 | 19.4% | 7.4% | ||
| Q3 25 | 13.2% | 20.5% | ||
| Q2 25 | 24.2% | 20.8% | ||
| Q1 25 | 21.9% | 19.5% | ||
| Q4 24 | 24.2% | 15.3% | ||
| Q3 24 | 29.8% | 22.6% | ||
| Q2 24 | 30.3% | 24.3% | ||
| Q1 24 | 27.9% | 21.0% |
純利益率AMPHCSW
| Q4 25 | 13.3% | 4.4% | ||
| Q3 25 | 9.0% | 14.7% | ||
| Q2 25 | 17.8% | 15.5% | ||
| Q1 25 | 14.8% | 15.2% | ||
| Q4 24 | 20.4% | 13.9% | ||
| Q3 24 | 21.1% | 15.8% | ||
| Q2 24 | 20.8% | 17.1% | ||
| Q1 24 | 25.1% | 15.1% |
EPS（希薄化後）AMPHCSW
| Q4 25 | $0.51 | $0.62 | ||
| Q3 25 | $0.37 | $2.41 | ||
| Q2 25 | $0.64 | $2.43 | ||
| Q1 25 | $0.51 | $2.05 | ||
| Q4 24 | $0.74 | $1.60 | ||
| Q3 24 | $0.78 | $2.26 | ||
| Q2 24 | $0.73 | $2.47 | ||
| Q1 24 | $0.81 | $2.03 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $40.2M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $1.1B |
| 総資産 | $1.6B | $2.3B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資AMPHCSW
| Q4 25 | $282.8M | $40.2M | ||
| Q3 25 | $276.2M | $31.5M | ||
| Q2 25 | $231.8M | $38.0M | ||
| Q1 25 | $236.9M | $225.8M | ||
| Q4 24 | $221.6M | $213.8M | ||
| Q3 24 | $250.5M | $273.2M | ||
| Q2 24 | $217.8M | $18.9M | ||
| Q1 24 | $289.6M | $22.2M |
総負債AMPHCSW
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | $800.1M | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | $166.0M |
株主資本AMPHCSW
| Q4 25 | $788.8M | $1.1B | ||
| Q3 25 | $776.7M | $1.1B | ||
| Q2 25 | $757.5M | $1.1B | ||
| Q1 25 | $751.3M | $1.1B | ||
| Q4 24 | $732.3M | $1.0B | ||
| Q3 24 | $727.7M | $1.0B | ||
| Q2 24 | $713.3M | $650.2M | ||
| Q1 24 | $672.4M | $615.7M |
総資産AMPHCSW
| Q4 25 | $1.6B | $2.3B | ||
| Q3 25 | $1.7B | $1.5B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.4B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.5B | $1.4B | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.6B | $1.0B |
負債/資本比率AMPHCSW
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | 0.75× | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | 0.27× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $28.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $22.7M |
| FCFマージンFCF / 売上 | 13.4% | 9.8% |
| 設備投資強度設備投資 / 売上 | 4.5% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 2.81× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $162.0M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローAMPHCSW
| Q4 25 | $32.9M | $28.9M | ||
| Q3 25 | $52.6M | $61.8M | ||
| Q2 25 | $35.6M | $60.6M | ||
| Q1 25 | $35.1M | $27.3M | ||
| Q4 24 | $29.0M | $11.6M | ||
| Q3 24 | $60.0M | $66.8M | ||
| Q2 24 | $69.1M | $62.7M | ||
| Q1 24 | $55.3M | $22.4M |
フリーキャッシュフローAMPHCSW
| Q4 25 | $24.6M | $22.7M | ||
| Q3 25 | $47.2M | $58.7M | ||
| Q2 25 | $25.0M | $57.7M | ||
| Q1 25 | $24.4M | $22.8M | ||
| Q4 24 | $16.6M | $8.5M | ||
| Q3 24 | $46.2M | $61.3M | ||
| Q2 24 | $63.1M | $59.6M | ||
| Q1 24 | $46.5M | $17.5M |
FCFマージンAMPHCSW
| Q4 25 | 13.4% | 9.8% | ||
| Q3 25 | 24.6% | 21.2% | ||
| Q2 25 | 14.3% | 21.9% | ||
| Q1 25 | 14.3% | 9.9% | ||
| Q4 24 | 8.9% | 4.4% | ||
| Q3 24 | 24.1% | 26.9% | ||
| Q2 24 | 34.6% | 26.3% | ||
| Q1 24 | 27.1% | 8.3% |
設備投資強度AMPHCSW
| Q4 25 | 4.5% | 2.6% | ||
| Q3 25 | 2.8% | 1.1% | ||
| Q2 25 | 6.1% | 1.1% | ||
| Q1 25 | 6.3% | 2.0% | ||
| Q4 24 | 6.7% | 1.6% | ||
| Q3 24 | 7.2% | 2.4% | ||
| Q2 24 | 3.3% | 1.4% | ||
| Q1 24 | 5.1% | 2.3% |
キャッシュ転換率AMPHCSW
| Q4 25 | 1.35× | 2.81× | ||
| Q3 25 | 3.03× | 1.52× | ||
| Q2 25 | 1.15× | 1.48× | ||
| Q1 25 | 1.39× | 0.78× | ||
| Q4 24 | 0.76× | 0.43× | ||
| Q3 24 | 1.48× | 1.85× | ||
| Q2 24 | 1.82× | 1.62× | ||
| Q1 24 | 1.28× | 0.71× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
